Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (Neptune II)

An Open-label, Long Term, Multi-center Study to Assess the Safety and Efficacy of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component

Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.

Study Overview

• Status: Completed
• Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
• Intervention / Treatment: Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg); Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)

Detailed Description

This is an open-label extension study following the double blind 905-CL-055 study

• Study Type: Interventional
• Enrollment (Actual): 1067
• Phase: Phase 3

Contacts and Locations

Study Locations

• Austria
  • Innsbruck, Austria, 6020
  • Vienna, Austria, 1090
• Belarus
  • Minsk, Belarus, 220036
  • Minsk, Belarus, 220119
  • Minsk, Belarus, 223040
• Belgium
  • Antwerp, Belgium, 2020
  • Edegem, Belgium, 2650
  • Gent, Belgium, 9000
  • Leuven, Belgium, 3000
  • Liege 1, Belgium, 4000
• Czechia
  • Hradec Kralove, Czechia, 500 02
  • Ostrava, Czechia, 700 30
  • Plzen, Czechia, 301 24
  • Roudnice nad Labem, Czechia, 413 01
  • Uherske Hradiste, Czechia, 686 08
  • Usti nad Labem, Czechia, 400 01
  • Zd'ar nad Sazavou, Czechia, 591 01
• France
  • Colmar Cedex, France, 68024
  • Montlucon, France, 03100
  • Orleans cedex 2, France, 45067
  • Paris, France, 75010
  • Paris Cedex 10, France, 75020
  • Pierre Benite, France, 69495
• Germany
  • Bautzen, Germany, 02625
  • Frankfurt, Germany, 65933
  • Ganderkesee, Germany, 27777
  • Hagenow, Germany, 19230
  • Halle Saale, Germany, 06132
  • Hamburg, Germany, 20253
  • Henningsdorf, Germany, 16761
  • Hettstedt, Germany, 06333
  • Koblenz, Germany, 56068
  • Leipzig, Germany, 04105
  • Leipzig, Germany, 04109
  • Lutherstadt Eisleben, Germany, 06295
  • Neustadt in Sachsen, Germany, 01844
  • Radebeul, Germany, 01445
  • Sachsen, Germany, 06526
  • Trier, Germany, 54290
  • Uetersen, Germany, 25436
• Italy
  • Avellino, Italy, 83100
  • Catanzaro, Italy, 88100
  • Palermo, Italy, 90146
  • Treviglio, Italy, 24047
• Netherlands
  • Amsterdam, Netherlands, 100 AD
  • Apeldoorn, Netherlands, 7334 DZ
  • Doetinchem, Netherlands, 7009 BL
  • Maastricht, Netherlands, 6229 HX
  • Sneek, Netherlands, 8600 BA
  • Tilburg, Netherlands, 5022 GC
  • Winterswijk, Netherlands, 7101 BN
• Poland
  • Bielsko-Biala, Poland, 43-300
  • Bydgoszcz, Poland, 85-094
  • Krakow, Poland, 31-530
  • Pulawy, Poland, 24-100
  • Warsaw, Poland, 02-005
  • Wiecbork, Poland, 89-410
• Slovakia
  • Nitra, Slovakia, 949 01
  • Piestany, Slovakia, 921 02
  • Presov, Slovakia, 080 01
  • Skalica, Slovakia, 909 82
  • Trencin, Slovakia, 911 01
• United Kingdom
  • Cardiff, United Kingdom, CF14 5GJ
  • Chorley, United Kingdom, PR7 7NA
  • Liverpool, United Kingdom, L22 0LG
  • Northwood, United Kingdom, HA6 2RN
  • Oxford, United Kingdom, OX3 7LJ
  • Reading, United Kingdom, RG2 7AG
  • Sheffield, United Kingdom, S10 2JF
  • Taunton, United Kingdom, TA1 5DA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Completion of 12 weeks double-blind treatment in Study 905-CL-055

Exclusion Criteria:

• Any significant PVR volume (>150 mL)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Total Group; Participants who received at least one dose of open-label fixed dose combination (FDC) treatment	Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg); oral; Other Names: Vesomni; EC905; Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg); oral; Other Names: EC905

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Adverse Events (AEs)	Safety is monitored by collecting AEs, which include abnormal lab parameters, vital signs or ECG data if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study drug or was clinically significant. A serious AE (SAE) was an AE resulting in death, persistent or significant disability/incapacity or congenital anomaly/birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. AEs were assessed by the Investigator for intensity (mild-no disruption of normal daily activities, moderate-affected normal daily activities or severe-inability to perform daily activities) and for causal relationship to study drug. A treatment-emergent adverse event (TEAE) was defined as an AE that occurred after the intake of first dose of double-blind study drug (if on FDC in 905-CL-055) or after first open-label dose until 30 days after the last dose of open-label study drug (in 905-CL-057).	From first dose of double-blind study drug (if on FDC in 905-CL-055) or first open-label dose up to 30 days after last dose of open-label study drug (in 905-CL-057) (up to 56 weeks)
Change From Baseline to End of Treatment in Post Void Residual (PVR) Volume	PVR volume is the volume of urine retained after voiding. PVR volume was assessed by ultrasonography or bladder scan.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)	Qmax during a micturition (urination) was recorded using uroflowmetry.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Average Flow Rate (Qmean)	Qmean during a micturition (urination) was recorded using uroflowmetry.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Total International Prostate Symptom Score (IPSS)	The International Prostate Symptom Score (IPSS) is a validated global questionnaire to assess the degree of urinary symptoms, based on answers to 7 questions concerning urinary symptoms: • Incomplete emptying of the bladder • Intermittency • Weak stream • Hesitancy • Frequency • Urgency • Nocturia Each question is assigned points from 0 to 5 indicating increasing severity of the symptom. Total score can range from 0 to 35 (mildly symptomatic to severely symptomatic).	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Total Urgency Frequency Score (TUFS) (Previously Known as Total Urgency Score [TUS])	The Patient Perception of the Intensity of Urgency Scale (PPIUS) is a validated scale completed as part of the micturition diary. For each micturition and/or incontinence episode, the participant rated the degree of associated urgency according to the following 5-point categorical scale: • 0. No urgency; • 1. Mild urgency; • 2. Moderate urgency; • 3. Severe urgency; • 4. Urgency incontinence TUS/TUFS was calculated as the sum of the PPIUS gradings from the 3-day diary divided by the number of days on which urgency grading was recorded. Higher scores indicate more severe urgency.	Baseline and up to 52 weeks of FDC treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours	A micturition is any voluntary urination, excluding episodes of incontinence only.The mean number of micturitions per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Mean Voided Volume Per Micturition	A micturition is any voluntary urination, excluding episodes of incontinence only. The mean volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Maximum Volume Voided Per Micturition	A micturition is any voluntary urination, excluding episodes of incontinence only. The maximum volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Mean Number of Urgency Episodes (PPIUS Grade 3 or 4) Per 24 Hours	An urgency episode is defined as an episode of strong desire to void accompanied by fear of leakage or pain. The mean number of urgency episodes with PPIUS grade 3 (Severe urgency) or 4 (Urgency incontinence) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours	An urgency incontinence episode is defined as an episode with any involuntary leakage of urine accompanied by or immediately preceded by urgency. The mean number of urgency incontinence episodes with PPIUS grade 3 (Severe incontinence) or 4 (Urgency incontinence) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours	An incontinence episode is defined as an episode with any involuntary loss of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Mean Number of Nocturia Episodes Per 24 Hours	A nocturia episode is defined as waking up at night to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the patient gets up in the morning with the intention to stay awake). The mean number of nocturia episodes per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Mean Number of Pads Used Per 24 Hours	The mean number of pads per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in IPSS Voiding Score	The IPSS is a validated global questionnaire to assess the degree of urinary symptoms based on answers to 7 questions. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The voiding score is the sum of the responses to 4 voiding questions (incomplete emptying of the bladder, intermittency, weak stream, hesitancy) and ranges from 0 to 20 (mildly symptomatic to severely symptomatic).	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in IPSS Storage Score	The IPSS is a validated global questionnaire to assess the degree of urinary symptoms based on answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The storage symptom score is the sum of the responses to 3 storage questions (frequency,urgency and nocturia) and ranges from 0 to 15 (mildly symptomatic to severely symptomatic).	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in IPSS Quality of Life (QoL) Score	The QoL assessment was a single question asking the participant how he would feel about tolerating his current level of symptoms for the rest of his life. The answers ranged from 0 to 6 (delighted to terrible).	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Symptom Bother Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The Symptom Bother portion consists of an 8-item scale scored from 1 to 6.The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. A negative change from baseline indicates an improvement.	Baseline and up to 52 weeks of FDC treatment
Number of OAB-q Responders Based on Health-related Quality of Life: Total Score	A OAB-q responder was defined as a participant with an improvement from baseline in HRQoL subscale total score ≥ 10.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in EQ-5D Visual Analogue Scale (VAS) Score	Visual Analogue Scale (VAS) is part of the EQ-5D questionnaire. The VAS is self-rated by the participant ranging from 0 to 100 (worst imaginable health state to best imaginable health state).	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Individual IPSS Scores	The IPSS is a validated global questionnaire to assess the degree of urinary symptoms, based on answers to 7 questions concerning urinary symptoms: • Incomplete emptying of the bladder • Intermittency • Weak stream • Hesitancy • Frequency • Urgency • Nocturia Each question is assigned points from 0 to 5 indicating increasing severity of the symptom.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Coping Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: • coping • concern • sleep • social interaction Coping score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Concern Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: • coping • concern • sleep • social interaction Concern score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Sleep Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: • coping • concern • sleep • social interaction Sleep score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Social Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: • coping • concern • sleep • social interaction Social score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Total Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: • coping • concern • sleep • social interaction Total score is calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in EQ-5D Mobility Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: • mobility • self-care • usual activity • pain/discomfort • anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = confined to bed).	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in EQ-5D Self-care Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: • mobility • self-care • usual activity • pain/discomfort • anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = unable to wash/dress).	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in EQ-5D Usual Activities Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: • mobility • self-care • usual activity • pain/discomfort • anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = unable to perform usual activities).	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in EQ-5D Pain/Discomfort Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: • mobility • self-care • usual activity • pain/discomfort • anxiety/depression Each domain has 3 response levels (1= no pain, 2= moderate pain, 3 = extreme pain).	Baseline and up to 52 weeks of FDC treatment
Change From Baseline to End of Treatment in EQ-5D Anxiety/Depression Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: • mobility • self-care • usual activity • pain/discomfort • anxiety/depression Each domain has 3 response levels (1= not anxious, 2= moderately anxious, 3 = extremely anxious).	Baseline and up to 52 weeks of FDC treatment

Collaborators and Investigators

• Sponsor: Astellas Pharma Europe B.V.
• Investigators: Study Chair: Use Central Contact, Astellas Pharma Global Development

Publications and helpful links

Helpful Links

• Link to results on Astellas Clinical Study Results website

Study record dates

Study Major Dates

• Study Start (Actual): April 26, 2010
• Primary Completion (Actual): December 14, 2011
• Study Completion (Actual): December 14, 2011

Study Registration Dates

• First Submitted: November 24, 2009
• First Submitted That Met QC Criteria: November 25, 2009
• First Posted (Estimated): November 26, 2009

Study Record Updates

• Last Update Posted (Actual): December 3, 2024
• Last Update Submitted That Met QC Criteria: November 12, 2024
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Keywords: Treatment; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms; Solifenacin succinate; EC905; Vesomni; Tamsulosin hydrochloride OCAS
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Pathologic Processes; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Urological Manifestations; Prostatic Hyperplasia; Hyperplasia; Lower Urinary Tract Symptoms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents; Adrenergic Agents; Urological Agents; Adrenergic Antagonists; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Tamsulosin; Solifenacin Succinate
• Other Study ID Numbers: 905-CL-057; 2008-001212-20 (EudraCT Number: EudraCT)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
• IPD Sharing Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
• IPD Sharing Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR